OCUL
Ocular Therapeutix, Inc Health Care Pharmaceutical Preparations Russell 3000
$6.97Close
$1.5BMarket cap
$6.29 – $16.1152-week range
Nov 3, 2026Next report
Highlights
Cautions
- Not in an uptrend 0 of 8 trend conditions
- Lagging the market RS 11 · weaker than 89% of stocks over 12 months
- Far from its high 57% below its 52-week high
- Results soon Nov 3, 2026, in 2 days
Price
Filing Results Screen pick 52-week high and low Adjusted prices
Key figures
Off 12-month high
57%
1wk
up 7.2%
price change
1mo
down 9.1%
price change
12-month return
down 41%
market up 11% ·
its own down 50%
F-score
4 / 9
Weak
Altman Z
3.92
Low risk
P/E
—
price / earnings
PEG
—
P/E / EPS growth
P/B
2.3×
price / book
Earnings yield
down 32.2%
EBIT / enterprise value
Cheaper than
24%
of the market · expensive
Revenue growth
down 18%
year on year
EPS growth
—
latest quarter
Sales growth
0%
latest quarter · -1 pts
ROE
down 55%
return on equity
Free cash margin
down 417%
-$216.9M FCF
D/E
0.11
long-term debt / equity
Net debt / EBITDA
—
Interest cover
—EBIT / interest
Piotroski tests
- not yet profitable on its assets
- operating cash flow is negative
- issued more shares
- gross margin narrowed
- assets working less efficiently
- profitability improving
- profits backed by cash
- reduced long-term debt
- short-term liquidity improved
Trade setup
ATR%
6.8%
$0.47 a day · 2×ATR $6.03
RS
11 / 99
vs the universe
Trend
0 / 8
trend template
Relative volume
0.9×
vs 50-day average
Up/down volume
0.68
50 sessions
Implied move
—
no option chain · report Nov 3, 2026
Trend template · 0 of 8
Screen verdict
Did not qualify for any screen.
Warning signs
- Shareholders diluted The share count rose 36.9% over the year, from 158m to 216m shares. Each existing share owns a smaller fraction of the company than it did a year ago.
- Gross margin narrowing Gross margin fell from 91.2% to 87.3%. The company is keeping less of each dollar of sales than it did a year ago.
- Revenue shrinking Revenue fell 18.5% over the year, from $63.7M to $52.0M.
Last reported
Aug 3, 2026
Last shock
Sep 28, 2026-21% in one session5.8× volumeno filing matched-9% since
Financials
- Gross 87%
- Net -512%
- Free cash -417%
- Cash
- Long-term debt
| FY2020Dec 31, 2020 | FY2021Dec 31, 2021 | FY2022Dec 31, 2022 | FY2023Dec 31, 2023 | FY2024Dec 31, 2024 | FY2025Dec 31, 2025 | |
|---|---|---|---|---|---|---|
| Revenue | $17.4M | $43.5M | $51.5M | $58.4M | $63.7M | $52.0M |
| Gross margin | 88% | 90% | 91% | 91% | 91% | 87% |
| Operating income | -$62.8M | -$78.0M | -$78.7M | -$82.4M | -$171.8M | -$270.0M |
| Net income | -$155.6M | -$6.6M | -$71.0M | -$80.7M | -$193.5M | -$265.9M |
| Net margin | -894% | -15% | -138% | -138% | -304% | -512% |
| Earnings per share | -$2.56 | -$0.08 | -$0.86 | -$0.94 | -$1.22 | -$1.42 |
| Free cash flow | -$54.4M | -$66.7M | -$63.3M | -$76.3M | -$136.0M | -$216.9M |
| Free cash margin | -313% | -153% | -123% | -131% | -213% | -417% |
| Cash | $228.1M | $164.2M | $102.3M | $195.8M | $392.1M | $737.1M |
| Long-term debt | $25.0M | $25.0M | $25.3M | $65.8M | $68.5M | $71.3M |
| Shareholders' equity | $76.1M | $88.0M | $35.4M | $91.1M | $315.3M | $654.3M |
| Shares outstanding | 76m | 76.73m | 77.20m | 114.96m | 157.75m | 215.93m |
Filings
| Filed | Report | Period to | Lag |
|---|---|---|---|
| Aug 3, 2026 | Quarterly ↗ | Jun 30, 2026 | 34d |
| May 5, 2026 | Quarterly ↗ | Mar 31, 2026 | 35d |
| Feb 5, 2026 | Annual ↗ | Dec 31, 2025 | 36d |
| Nov 4, 2025 | Quarterly ↗ | Sep 30, 2025 | 35d |
| Aug 5, 2025 | Quarterly ↗ | Jun 30, 2025 | 36d |
| May 5, 2025 | Quarterly ↗ | Mar 31, 2025 | 35d |
| Mar 3, 2025 | Annual ↗ | Dec 31, 2024 | 62d |
| Nov 14, 2024 | Quarterly ↗ | Sep 30, 2024 | 45d |
| Aug 7, 2024 | Quarterly ↗ | Jun 30, 2024 | 38d |
| May 7, 2024 | Quarterly ↗ | Mar 31, 2024 | 37d |
| Mar 11, 2024 | Annual ↗ | Dec 31, 2023 | 71d |
| Nov 7, 2023 | Quarterly ↗ | Sep 30, 2023 | 38d |
Current reports
| Filed | Disclosed |
|---|---|
| Oct 16, 2026 | Director or officer change ↗ |
| Aug 3, 2026 | Results ↗ |
| Jun 12, 2026 | Director or officer change · Shareholder vote ↗ |
| May 5, 2026 | Results ↗ |
| Feb 27, 2026 | Regulation FD ↗ |
| Feb 5, 2026 | Results ↗ |
| Jan 23, 2026 | Director or officer change ↗ |
| Dec 18, 2025 | Other events ↗ |
| Dec 5, 2025 | Other events ↗ |
| Nov 4, 2025 | Results ↗ |
| Sep 30, 2025 | Material agreement · Other events ↗ |
| Sep 30, 2025 | Other events ↗ |